CONTINGENT ANNUAL BONUS AGREEMENTContingent Annual Bonus Agreement • May 3rd, 2007 • Pozen Inc /Nc • Pharmaceutical preparations
The undersigned employee, Marshall E. Reese (the “Employee”), acknowledges and agrees that on December 20, 2006, the Compensation Committee of the POZEN Inc. (the “Company”) approved, as a part of Employee’s annual cash bonus for 2006, a contingent bonus amount of $48,256.00 (the “Contingent Bonus”) to Employee, payable as described below and subject to the fulfillment of certain conditions as set forth herein. Employee acknowledges and agrees that, pursuant to the Compensation Committee approval, the Contingent Bonus shall not be paid unless and until the Company has received an action letter from the U.S. Food and Drug Administration indicating approval of the New Drug Application for Trexima, the proposed brand name for the combination of GlaxoSmithKline’s sumatriptan and naproxen sodium in a single tablet being developed by the Company for the acute treatment of migraine pursuant to a development and commercialization agreement with GlaxoSmithKline (the “Trexima Approval”) provided
CONTINGENT ANNUAL BONUS AGREEMENTContingent Annual Bonus Agreement • May 3rd, 2007 • Pozen Inc /Nc • Pharmaceutical preparations
The undersigned employee, John R. Plachetka (the “Employee”), acknowledges and agrees that on February 14, 2007, the Compensation Committee of the Board of Directors of POZEN Inc. (the “Company”) approved, as a part of Employee’s annual cash bonus for 2006, a contingent bonus amount of $75,075.00 (the “Contingent Bonus”) to Employee, payable as described below and subject to the fulfillment of certain conditions as set forth herein. Employee acknowledges and agrees that, pursuant to such approval, the Contingent Bonus shall not be paid unless and until the Company has received an action letter from the U.S. Food and Drug Administration indicating approval of the New Drug Application for Trexima, the proposed brand name for the combination of GlaxoSmithKline’s sumatriptan and naproxen sodium in a single tablet being developed by the Company for the acute treatment of migraine pursuant to a development and commercialization agreement with GlaxoSmithKline (the “Trexima Approval”) provided
